Leading Direct to Consumer Vagus Nerve Stimulator Available for Purchase on World’s Largest Retail Platform Leading Direct to Consumer Vagus Nerve Stimulator Available for Purchase on World’s Largest Retail Platform
BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases. The Phase 1b trial will primarily evaluate the safety of VYN202, administered orally once a day for 12 weeks, with secondary objectives to evaluate the pharmacokinetic profile and preliminary evidence of efficacy, including improvement from baseline in psoriasis area and severity index (PASI) scores. Top-line data from the 12-week randomized, placebo-controlled trial are expected by year-end 2025.
Go here to see the original:
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator (“PI”) for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer’s disease (NCT06189963). In addition to Dr. Fletcher’s appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orlando will be the first clinical site on the East Coast with the intent of enrolling moderate stage Alzheimer’s Disease (AD) patients in the very near term.
Read more from the original source:
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with...
EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.
See the rest here:
4DMT to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.
Read this article:
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose
The rest is here:
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience significant relief from abdominal pain when following a dietary therapy created and guided by the inFoods® IBS blood test. The findings from a clinical trial published in Gastroenterology, demonstrate that participants who adhered to a personalized diet therapy based on the test results experienced greater symptom improvement compared to those following a sham (placebo) elimination diet.
Go here to see the original:
Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal
Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- eXoZymes, Inc. (Nasdaq: EXOZ) (“eXoZymes”) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen will be joined by eXoZymes team members to ring the Nasdaq Stock Market (“Nasdaq”) closing bell on Wednesday, February 19, 2025. This comes following a successful initial public offering of common stock at $8 per share, which closed on November 14, 2024.
More:
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering
DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and full year 2024 results followed by Q&A on Wednesday, March 12th, 2025, at 8:00 a.m. ET.
See the rest here:
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of America’s Best Employers 2025. This prestigious recognition is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.
Read more:
Myriad Genetics Included in Forbes America’s Best Employers 2025 List